RC148 

RC148 is a humanized IgG1 bispecific antibody targeting VEGF and PD-1. RC148 allows dimeric VEGF crosslinking and gradually enhances PD-1 binding activity, potentially reduces systemic toxicity of the anti-VEGF approach, and enhances antitumor potency via VEGF-triggered enrichment in tumor areas. RC148 blocks the binding of VEGF to VEGFR and PD-1 to PD-L1, prevents the growth and migration of human umbilical vein endothelial cells, and enables efficient T cell activation. RC148 can be used for the study of breast cancer and lung cancer^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

29126  [NCBI] & 7422  [NCBI]

Q9NZQ7 & P15692

PD-1 & VEGF

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

167.34 kDa

Liquid

Colorless to light yellow

N/A

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Human PD1 Protein, His Tag can bind RC148. The EC₅₀ for this effect is 148.6 ng/mL.
• 
  Immobilized Human VEGF165 Protein, hFc Tag can bind RC148. The EC₅₀ for this effect is 106 ng/mL.

• [1]. Jianmin Fang, et al. RC148, a novel bispecific antibody targeting PD-1 and VEGF for cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2734.